Lv1
82 积分 2023-12-02 加入
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
1个月前
已完结
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
2个月前
已完结
Regulated necrosis at the crossroads of liver inflammation and cancer development
3个月前
已完结
The origin of hepatocellular carcinoma depends on metabolic zonation
3个月前
已完结
Improving surgical treatments for hepatocellular carcinoma
3个月前
已完结
Integrated therapies for targeting the microenvironment of hepatocellular carcinoma
3个月前
已完结
Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma
4个月前
已完结
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion
6个月前
已完结
The side effects of platinum-based chemotherapy drugs: a review for chemists
6个月前
已完结
Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival
7个月前
已完结
皖公网安备34019202002308
